The Molecular Epidemiological Study of HCV Subtypes among Intravenous Drug Users and Non-Injection Drug Users in China

被引:8
|
作者
Tao, Jun [1 ]
Liang, Jun [2 ]
Zhang, Hui [2 ]
Pei, Lijian [2 ]
Qian, Han-zhu [1 ,3 ]
Chambers, Matthew C. [4 ]
Jiang, Yan [2 ]
Xiao, Yao [2 ]
机构
[1] Vanderbilt Univ, Vanderbilt Inst Global Hlth, Nashville, TN 37235 USA
[2] Chinese Ctr Dis Control & Prevent China CDC, Natl AIDS Reference Lab NARL, Natl Ctr AIDS STD Control & Prevent NCAIDS, Beijing, Peoples R China
[3] Vanderbilt Univ, Dept Med, Nashville, TN USA
[4] Vanderbilt Univ, Dept Biomed Informat, Nashville, TN 37235 USA
来源
PLOS ONE | 2015年 / 10卷 / 10期
关键词
HEPATITIS-C VIRUS; PEGYLATED INTERFERON; VIROLOGICAL RESPONSE; RISK FACTOR; HIV; THERAPY; SEROCONVERSION; TRANSMISSION; COMBINATION; PREVALENCE;
D O I
10.1371/journal.pone.0140263
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background More than half of intravenous drug users (IDUs) in China suffer from the Hepatitis C virus (HCV). The virus is also more prevalent in non-injection drug users (NIDUs) than in the general population. However, not much is known about HCV subtype distribution in these populations. Methods Our research team conducted a cross-sectional study in four provinces in China. We sampled 825 IDUs and 244 NIDUs (1162 total), genotyped each DU's virus, and performed a phylogenetic analysis to differentiate HCV subtypes. Results Nucleic acid testing (NAT) determined that 82% percent (952/1162) of samples were HCV positive; we subtyped 90% (859/952) of these. We found multiple HCV subtypes: 3b (249, 29.0%), 3a (225, 26.2%), 6a (156, 18.2%), 1b (137, 15.9%), 6n (50, 5.9%), 1a (27, 3.1%), and 2a (15, 1.7%). An analysis of subtype distributions adjusted for province found statistically significant differences between HCV subtypes in IDUs and NIDUs. Discussion HCV subtypes 3b, 3a, 6a, and 1b were the most common in our study, together accounting for 89% of infections. The subtype distribution differences we found between IDUs and NIDUs suggested that sharing syringes was not the most likely pathway for HCV transmission in NIDUs. However, further studies are needed to elucidate how NIDUs were infected.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Stability of liver fibrosis among HCV-infected injection drug users
    Mehta, Shruti H.
    Kirk, Gregory D.
    Astemborski, Jacquie
    Sulkowski, Mark S.
    Afdhal, Nezam H.
    Thomas, David L.
    ANTIVIRAL THERAPY, 2012, 17 (05) : 813 - 821
  • [42] The onset of drug injection among sex partners of injection drug users
    Ouellet, LJ
    Rahimian, A
    Wiebel, WW
    AIDS EDUCATION AND PREVENTION, 1998, 10 (04) : 341 - 350
  • [43] Rationale to Evaluate Medically Supervised Safer Smoking Facilities for Non-injection Illicit Drug Users
    Courtney L. C. Collins
    Thomas Kerr
    Mark W. Tyndall
    David C. Marsh
    Patricia S. Kretz
    Julio S. Montaner
    Evan Wood
    Canadian Journal of Public Health, 2005, 96 : 344 - 347
  • [44] Rationale to evaluate medically supervised safer smoking facilities for non-injection illicit drug users
    Collins, CLC
    Kerr, T
    Tyndall, MW
    Marsh, DC
    Kretz, PS
    Montaner, JS
    Wood, E
    CANADIAN JOURNAL OF PUBLIC HEALTH-REVUE CANADIENNE DE SANTE PUBLIQUE, 2005, 96 (05): : 344 - 347
  • [45] TT virus infection among intravenous drug users in southwest China
    Cao, K
    Mizokami, M
    Orito, E
    Ding, X
    Ge, XM
    Huang, GY
    Ueda, R
    HEPATOLOGY, 1998, 28 (04) : 292A - 292A
  • [46] Hepatitis C among intravenous drug users
    Maher, L
    Jalaludin, B
    Chant, K
    Kaldor, J
    EPIDEMIOLOGY, 2005, 16 (03) : 423 - 423
  • [47] INFECTIVE ENDOCARDITIS AMONG INTRAVENOUS DRUG USERS
    Abbasi, Farhad
    Besharat, Mehdi
    Kiyani, Jamile
    IRANIAN JOURNAL OF PUBLIC HEALTH, 2014, 43 : 191 - 191
  • [48] High HCV seroprevalence and HIV drug use risk behaviors among injection drug users in Pakistan
    Kuo I.
    ul-Hasan S.
    Galai N.
    Thomas D.L.
    Zafar T.
    Ahmed M.A.
    Strathdee S.A.
    Harm Reduction Journal, 3 (1)
  • [49] Microbiology and Initial Antibiotic Therapy for Injection Drug Users and Non-Injection Drug Users with Cutaneous Abscesses in the Era of Community-associated Methicillin-resistant Staphylococcus aureus
    Jenkins, Timothy C.
    Knepper, Bryan C.
    Moore, S. Jason
    Saveli, Carla C.
    Pawlowski, Sean W.
    Perlman, Daniel M.
    McCollister, Bruce D.
    Burman, William J.
    ACADEMIC EMERGENCY MEDICINE, 2015, 22 (08) : 993 - 997
  • [50] Differences in HCV subtype distribution according to primary drug of choice among injection drug users.
    Krekulova, L
    Rehak, V
    Johnson, M
    Riley, LW
    HEPATOLOGY, 2001, 34 (04) : 564A - 564A